Achieve Life Sciences (ACHV) Q1 2024: $124M Financing Secured as NDA Pathway Clears for Cytosinicline

May 9, 2024 | By EarningsIQ Research

ACHV’s Q1 was defined by regulatory clarity, substantial new funding, and tangible clinical momentum for cytosinicline. FDA alignment on long-term safety requirements and the $124 million capital raise provide operational runway and strategic optionality as the company advances toward NDA submission. Investor focus now shifts to ORCA-OL enrollment and the dual opportunity in smoking and vaping cessation.

Summary

• Regulatory Milestone Achieved: FDA agreement on long-term exposure data requirements removes a critical NDA hurdle.
• Financial Runway Extended: $124 million financing ensures execution of pivotal ORCA-OL trial and supports operations through key milestones.
• Clinical Expansion in Focus: Label expansion discussions for e-cigarette cessation position cytosinicline for broader market impact.

Business Overview

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing cytosinicline, a novel, plant-derived nicotinic receptor partial agonist, for the treatment of nicotine dependence. The company’s revenue model will be driven by the commercialization of cytosinicline for smoking cessation and, pending regulatory approval, vaping cessation. Its major value-creation activities are centered on clinical development, regulatory approval, and future commercialization partnerships.

Performance Analysis

Q1 marked a pivot from resource constraint to operational readiness. Achieve secured up to $124 million in new capital through a direct offering and private placement, with $60 million received upfront and $64.2 million tied to warrant exercises. This infusion ensures funding for the pivotal ORCA-OL study and extends the company’s cash runway well past the anticipated NDA submission in the first half of 2025, potentially into 2026 if all warrants are exercised.

Operating expenses decreased to $6 million versus $8.6 million in the prior year, reflecting a pause between major trial activities, while the net loss narrowed accordingly. However, management guided that both expenses and net loss will rise as ORCA-OL ramps up, underscoring the shift from preparatory to execution mode. The company ended the quarter with $66.4 million in cash equivalents, providing a solid buffer as it initiates the next phase of clinical work.

• Financing Upside: The capital raise included participation from new healthcare investors and manufacturing partner Sofarma, signaling external validation of the cytosinicline opportunity.
• Expense Management: Lower Q1 expenses are temporary, with spend set to increase as the ORCA-OL trial enrolls and progresses.
• Runway Visibility: Funding is projected to cover operations through key regulatory milestones and potential product approval.

With the financial overhang addressed and regulatory clarity in hand, Achieve is positioned to accelerate its clinical program and pursue commercial partnership discussions from a position of strength.

Executive Commentary

Strategic Positioning

1. Regulatory Alignment Accelerates Path to Market

FDA agreement on long-term exposure requirements for cytosinicline removes a major gating factor for NDA submission. The ORCA-OL trial will leverage prior trial participants, expediting data collection and reducing time to regulatory filing. The FDA’s acceptance of cumulative (not continuous) exposure allows for efficient subject enrollment and data integration.

2. Dual Indication Strategy for Smoking and Vaping

Cytosinicline is being positioned for both traditional smoking and e-cigarette cessation, a notable differentiator. The recently published ORCAv1 data in JAMA demonstrated a doubling of vaping abstinence rates versus placebo, and FDA has indicated that the ongoing long-term safety trial will support both indications, simplifying development and maximizing addressable market potential.

3. Capital Strength and Investor Validation

The $124 million financing, including participation from the manufacturing partner Sofarma, provides operational runway and signals confidence in Achieve’s clinical and commercial trajectory. This capital not only funds the ORCA-OL trial and NDA preparation but also enhances Achieve’s leverage in future partnership negotiations.

4. Clinical Execution and Site Strategy

All 29 clinical sites for ORCA-OL participated in prior successful studies, and targeted outreach to over 1,100 previously treated subjects is expected to drive rapid enrollment. The ability to enroll both prior cytosinicline and placebo subjects further de-risks trial execution and supports robust safety data generation.

Key Considerations

Achieve’s Q1 reflects a transition from regulatory uncertainty to execution mode, with significant implications for both operational focus and investor expectations in 2024.

Key Considerations:

• Regulatory Pathway Clarity: Alignment with FDA on exposure requirements streamlines the NDA process and reduces development risk.
• Broadened Clinical Label Potential: Simultaneous pursuit of smoking and vaping cessation indications positions cytosinicline for first-mover advantage in the e-cigarette market.
• Operational Leverage: Efficient use of existing trial infrastructure and subject pools is expected to accelerate ORCA-OL enrollment and data collection.
• Market Opportunity Validation: Strong interest from new investors and partners, including Sofarma, reflects growing confidence in the commercial potential of cytosinicline.

Risks

Execution risk remains around timely enrollment and data quality for the ORCA-OL trial, despite high subject interest. Regulatory timelines, while clarified, are still subject to delays. The company’s future revenue is entirely dependent on cytosinicline’s approval and successful commercialization, and competitive threats from existing or new cessation therapies could impact uptake. Finally, as a single-product company, Achieve remains exposed to binary clinical and regulatory outcomes.

Forward Outlook

For Q2 and the remainder of 2024, Achieve guided to:

• Initiation of ORCA-OL enrollment within weeks, with completion targeted for 2024.
• Preparation for NDA submission for smoking cessation in the first half of 2025.

For full-year 2024, management maintained guidance:

• Cash runway through NDA submission, with potential extension into 2026 if all warrants are exercised.

Management highlighted several factors that will drive near-term progress:

• Operational focus on rapid ORCA-OL enrollment and data collection.
• Engagement with FDA for label expansion discussions for vaping cessation.

Takeaways

ACHV enters a critical execution window, with regulatory clarity, robust funding, and a clear clinical focus. The next inflection will be ORCA-OL enrollment progress and continued regulatory engagement.

• Funding and Regulatory Alignment: With capital secured and FDA requirements set, Achieve’s near-term risk profile is reduced and focus turns to trial execution.
• Market Expansion Optionality: The company’s dual-pronged approach for smoking and vaping cessation could unlock a broader patient population and first-mover advantage.
• Watch Enrollment and Partnership Progress: Investors should monitor ORCA-OL enrollment pace and any signals of commercial or strategic partnering as key catalysts for value creation.

Conclusion

Achieve Life Sciences exits Q1 2024 with regulatory clarity, financial strength, and a focused clinical agenda. The company’s progress on cytosinicline development and capital raise sets the stage for pivotal execution milestones in the coming quarters.

Industry Read-Through

ACHV’s alignment with FDA on cumulative exposure requirements and the dual indication pursuit for cytosinicline highlight a growing regulatory openness to streamlined development paths for addiction therapeutics. The strong investor appetite for the financing, including manufacturing partner participation, signals renewed interest in smoking and vaping cessation markets, especially given the lack of new FDA-approved therapies in nearly two decades. For biopharma peers, ACHV’s approach to leveraging prior trial data and efficient site activation offers a template for cost-effective late-stage development. The company’s focus on both traditional and e-cigarette cessation may also serve as a catalyst for broader investment and innovation in addiction medicine, where unmet need and public health impact remain high.

ACHV Healthcare Biotechnology Drug Development Smoking Cessation Vaping Regulatory Clinical Trials